12:22:51 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-05-10 Ordinarie utdelning REDS 0.00 SEK
2024-05-08 Kvartalsrapport 2024-Q1
2024-05-08 Årsstämma 2024
2024-02-27 Bokslutskommuniké 2023
2023-11-09 Kvartalsrapport 2023-Q3
2023-08-29 Kvartalsrapport 2023-Q2
2023-05-10 Ordinarie utdelning REDS 0.00 SEK
2023-05-09 Kvartalsrapport 2023-Q1
2023-05-09 Årsstämma 2023
2023-02-27 Bokslutskommuniké 2022
2022-11-09 Kvartalsrapport 2022-Q3
2022-08-29 Kvartalsrapport 2022-Q2
2022-05-03 Ordinarie utdelning REDS 0.00 SEK
2022-05-02 Årsstämma 2022
2022-05-02 Kvartalsrapport 2022-Q1
2022-02-28 Bokslutskommuniké 2021
2021-11-09 Kvartalsrapport 2021-Q3
2021-08-24 Kvartalsrapport 2021-Q2
2021-05-12 Årsstämma 2021
2021-05-05 Ordinarie utdelning REDS 0.00 SEK
2021-05-03 Kvartalsrapport 2021-Q1
2021-04-19 Extra Bolagsstämma 2021
2021-02-28 Bokslutskommuniké 2020
2020-12-18 Extra Bolagsstämma 2020
2020-11-09 Kvartalsrapport 2020-Q3
2020-08-24 Kvartalsrapport 2020-Q2
2020-06-23 Ordinarie utdelning REDS 0.00 SEK
2020-06-22 Årsstämma 2020
2020-05-04 Kvartalsrapport 2020-Q1
2020-02-25 Bokslutskommuniké 2019
2019-11-18 Kvartalsrapport 2019-Q3
2019-08-26 Kvartalsrapport 2019-Q2
2019-05-07 Ordinarie utdelning REDS 0.00 SEK
2019-05-06 Årsstämma 2019
2019-05-06 Kvartalsrapport 2019-Q1
2019-02-26 Bokslutskommuniké 2018
2018-08-27 Kvartalsrapport 2018-Q2
2018-05-08 Ordinarie utdelning REDS 0.00 SEK
2018-05-07 Årsstämma 2018
2018-02-27 Bokslutskommuniké 2017
2017-09-25 Extra Bolagsstämma 2017
2017-08-28 Kvartalsrapport 2017-Q2
2017-04-06 Ordinarie utdelning REDS 0.00 SEK
2017-04-05 Årsstämma 2017
2017-02-22 Bokslutskommuniké 2016
2016-10-26 Kvartalsrapport 2016-Q3
2016-08-25 Kvartalsrapport 2016-Q2
2016-05-09 Årsstämma 2016
2016-05-09 Kvartalsrapport 2016-Q1
2016-02-23 Ordinarie utdelning REDS 0.00 SEK
2016-02-22 Bokslutskommuniké 2015
2015-11-27 Kvartalsrapport 2015-Q3

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
Redsense Medical är ett medicinteknikbolag som är specialiserat inom utvecklingen av blodläckage-alarm. Bolagets produkt fungerar som en sensor baserad på fiberteknik som snabbare skall upptäcka blodförlust, samt larma och rapportera till olika larmenheter. Utöver huvudverksamheten erbjuds träning och utbildning inom affärsområdet. Bolaget grundades år 2006 och har sitt huvudkontor i Halmstad.
2018-11-13 12:26:59

Today, Redsense Medical announces that the company has developed a new technology platform for smart optical measuring of substances such as blood and exudate, by using for example temperature and pressure in bandages or adhesive plasters. Discussions have been initiated with global wound care companies, and a first patent application has been filed.

The new technology is an improvement upon Redsense's patented technology platform that is utilized in the company's blood leakage alarm used for increased patient safety during hemodialysis. It enables a more precise optical measurement of several physical and biological parameters. There is interest from global companies in the wound care sector, and initial discussions have been initiated. 

"Just as the Redsense blood leakage alarm did in hemodialysis, we now want to revolutionize patient safety during wound care treatment with this smart optical sensor technology. This is another area where we can enable lower costs of care and more individual treatment programs. There is initial interest from global wound care companies to develop their products with new technology, and our innovation can provide this in a cost-effective way," says Redsense Medical's CEO Patrik Byhmer.

The wound care market was valued at approximately USD 18 billion in 2016, and it is expected to grow at a CAGR of 5.3 % until 2023. The primary drivers of market growth are an ageing global population, a larger number of diabetics and increasing investments in research and development, which is also expected to lead to new research discoveries in this area. Chronic wounds are expected to constitute most of the wound care market up until 2022.

"We are aiming to address the market for advanced wound care with an estimated market size of 100 billion SEK. When looking specifically at burn wounds, we estimate that the part of the market where we see a strong interest in our product is worth approximately 20 billion SEK. We will develop an OEM business model where we work with established companies in the sector," says Patrik Byhmer. 

Redsense emphasizes that Redsense Medical has no need of any additional external capital injection to continue to develop the new application area. Other solutions for the financing are possible and are now discussed, including a new listing in a separate company. 

"Because of the significant interest in this technology, and the very large global market for wound care products, we expect to find the funds to finance this. The challenge is rather to find the right framework for the development to create optimal value for the company and the shareholders. A separate listing could be appropriate as the technology has potential in several market areas. Redsense could then continue to be a pure medical technology company with the aim to reach a positive cash flow in the reasonably near future, something we have good hopes of achieving. We see this possibility to broaden our product range as a contributing factor in taking Redsense Medical to a whole new level," says Patrik Byhmer.

Redsense has already proven that the technology works as intended. The company has also filed a first patent application that will be the starting point for a global patent strategy. The next step will be to develop a functioning prototype of the smart optic sensor that can be evaluated by potential partners.